Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy

Zhang, Fan; Huang, Di; Lei, Z. H.; Li, Tao; Zhang, Sujie; Zhang, Guoqing; Fang, Yuan; Zhang, Jie; Zhang, Yuzi; Zhao, Zhengyi; Cui, Longgang; Zhao, Jing; Wang, Guoqiang; Cai, Shangli; Bai, Yuezong; Wang, Jinliang; Hu, Yi

doi:10.1177/1758835920936882

Cited by 17 publications

(20 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of safety, the incidence of AEs was low among patients in this study; grade 3-4 AEs were rare. This suggests that the nab-paclitaxel plus PD-1 inhibitor combination has a favorable safety profile, which is in accordance with the findings of previous studies [24,32]; the safety profile of this combination regimen is significantly better than that of paclitaxel plus gemcitabine for STS therapy [26,33]. This can greatly improve the satisfaction and quality of life of patients undergoing treatment.…”

Section: Table 2 Responses Of Various Histological Subtypes To Treatmentsupporting

confidence: 89%

“…Nab-paclitaxel is a well-known inducer of immunogenic cell death and has been shown to improve the efficacy of PD-1 inhibitors via the regulation of various immune functions [25,31]. The synergistic effect of nab-paclitaxel combined with a PD-1 inhibitor has been demonstrated [23][24][25]32]. Therefore, the aforementioned combination regimen was selected for the treatment of our patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

et al. 2022

View full text Add to dashboard Cite

Background There is increasing evidence that combination therapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and programmed cell death protein 1 (PD-1) inhibitor is safe and efficacious in treating many types of malignant tumors. However, clinical data demonstrating the effect of this treatment combination for patients with metastatic soft tissue sarcoma (STS) are currently limited. Methods The clinical data of patients with metastatic STS who received nab-paclitaxel plus PD-1 inhibitor (sintilimab) therapy between January 2019 and February 2021 were retrospectively analyzed. The effectiveness and safety of the combined treatment were evaluated in terms of the median progression-free survival (PFS), estimated using the Kaplan–Meier method. The univariate Cox proportional hazards model was used to analyze the relationship between clinicopathological parameters and PFS. All statistical analyses were two-sided; P < 0.05 was considered statistically significant. Results A total of 28 patients treated with nab-paclitaxel plus sintilimab were enrolled in this study. The objective response rate was 25%, the disease control rate was 50%, and the median PFS was 2.25 months (95% CI = 1.8–3.0 months). The most common grade 1 or 2 adverse events (AEs) were alopecia (89.3%; 25/28), leukopenia (25.0%; 7/28), fatigue (21.4%; 6/28), anemia (21.4%; 6/28), and nausea (21.4%; 6/28). The most common grade 3 AEs were neutropenia (10.7%; 3/28) and peripheral neuropathy (10.7%; 3/28). No grade 4 AEs were observed. Among the present study cohort, patients with angiosarcoma (n = 5) had significantly longer PFS (P = 0.012) than patients with other pathological subtypes, including undifferentiated pleomorphic sarcoma (n = 7), epithelioid sarcoma (n = 5), fibrosarcoma (n = 4), synovial sarcoma (n = 3), leiomyosarcoma (n = 2), pleomorphic liposarcoma (n = 1), and rhabdomyosarcoma (n = 1); those who experienced three or more AEs had significantly longer median PFS than those who experienced less than three AEs (P = 0.018). Conclusion Nab-paclitaxel plus PD-1 inhibitor is a promising treatment regimen for advanced STS. Randomized controlled clinical trials are required to further demonstrate its efficacy and optimal application scenario.

show abstract

Section: Table 2 Responses Of Various Histological Subtypes To Treatmentsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, no clinical study has directly compared immunotherapy with immunotherapy + chemotherapy in the second-line treatment of NSCLC. Only a small retrospective study indicated that PD-1/PD-L1 inhibitor + nab-paclitaxel showed significantly longer OS and higher response than PD-1/PD-L1 inhibitor monotherapy in second-line and above therapy for NSCLC [13]. However, the majority of patients in the study received third-line and above therapy (65%), and different types of PD-1/PD-L1 inhibitors were included, which were unreported.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC

Wang

Nie

Dai

et al. 2021

Cancer Immunol Immunother

Self Cite

View full text Add to dashboard Cite

Background The combination of PD-1/PD-L1 inhibitor and chemotherapy has been clinically confirmed to be beneficial as the first-line treatment of patients with advanced NSCLC. This study aimed to assess the effect of nivolumab + docetaxel versus nivolumab monotherapy in patients with NSCLC after the failure of platinum doublet chemotherapy. Materials and methods The efficacy and toxicity of nivolumab + docetaxel combination therapy versus nivolumab monotherapy were compared in this retrospective study. Primary endpoint of the study was progression-free survival (PFS), and the secondary endpoints were objective response rate (ORR), overall survival (OS), and toxicity. Results Between November 2017 and December 2019, 77 patients were included in this study, with 58 patients in the nivolumab group and 19 in the nivolumab + docetaxel group. The median follow-up was 18 months, and the PFS was 8 months for patients receiving nivolumab + docetaxel and 2 months for those receiving nivolumab alone (p = 0.001), respectively. Nivolumab + docetaxel showed superior OS compared with nivolumab, with the median OS unreached versus 7 months (p = 0.011). Among patients without EGFR/ALK variation, compared to nivolumab monotherapy, nivolumab + docetaxel showed better PFS (p = 0.04) and OS (p = 0.05). There was no significant difference in grade 3–4 adverse events (AEs) between the two groups (p = 0.253). Conclusions The combination of nivolumab and docetaxel demonstrated a meaningful improvement in progression-free survival and overall survival compared to nivolumab monotherapy, in patients with NSCLC after the failure of platinum doublet chemotherapy, irrespective of EGFR/ALK variation status.

show abstract

“…Zhang et al. ( 133 ) conducted a study on the use of PD-1/PD-L1 inhibitors in separate inhibitors monotherapy and combined with nab-paclitaxel in patients with small cell carcinoma of the lung, found median OS values of 28.6 months and 15.9 months in the nab-paclitaxel and monotherapy groups, respectively. The results reflect the effectiveness of the combination, but this combination still needs to be further explored due to the lack of a control group using chemotherapy alone.…”

Section: Combination With Chemotherapeutic Drugsmentioning

confidence: 99%

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

Sun

Cheng

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

The occurrence and development of cancer are closely related to the immune escape of tumor cells and immune tolerance. Unlike previous surgical, chemotherapy, radiotherapy and targeted therapy, tumor immunotherapy is a therapeutic strategy that uses various means to stimulate and enhance the immune function of the body, and ultimately achieves the goal of controlling tumor cells.With the in-depth understanding of tumor immune escape mechanism and tumor microenvironment, and the in-depth study of tumor immunotherapy, immune checkpoint inhibitors represented by Programmed Death 1/Programmed cell Death-Ligand 1(PD-1/PD-L1) inhibitors are becoming increasingly significant in cancer medication treatment. employ a variety of ways to avoid detection by the immune system, a single strategy is not more effective in overcoming tumor immune evasion and metastasis. Combining different immune agents or other drugs can effectively address situations where immunotherapy is not efficacious, thereby increasing the chances of success and alternative access to alternative immunotherapy. Immune combination therapies for cancer have become a hot topic in cancer treatment today. In this paper, several combination therapeutic modalities of PD1/PD-L1 inhibitors are systematically reviewed. Finally, an analysis and outlook are provided in the context of the recent advances in combination therapy with PD1/PD-L1 inhibitors and the pressing issues in this field.

show abstract

Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy

Cited by 17 publications

References 47 publications

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

Contact Info

Product

Resources

About